Peter Bach, MD, MAPP, and his Drug Pricing Lab at Memorial Sloan Kettering (MSK) argue profit caps will do better than the current biosimilar system.
The US biosimilars market has been slow to develop, and 6 years after the first biosimilar appeared on market, biosimilars are available in just 7 drug categories and average discounts from originators afforded by these agents are 30%. To some, this pace of biosimilar adoption and the savings achieved are not adequate.
In a report, the longtime drug pricing critic Peter Bach, MD, MAPP, director of the Drug Pricing Lab and Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, has proposed that after a 12-year window of product exclusivity, profits on originator biologics should be capped at 10% above costs of production and distribution.
In what Bach and his co-authors have dubbed the “P-quad” system, prices on originator products would likely drop by 35%. P-quad stands for Production Plus Profit Pricing. “We propose that it is time to assess the success of the [Biologics Price Competition and Innovation Act] 11 years after its passage. Both evidence and market realities suggest biosimilar policy is not achieving its intended objective,” they wrote.
The Milliman Report
According to a supporting study prepared by the actuarial and consulting company Milliman for the Drug Pricing Lab, under a scenario of the P-quad system and biosimilar competition combined, federal government health plans would save $140 billion from 2021 through 2025, vs an anticipated $45 billion under the current system, which allows originator and biosimilar companies to set their own prices. Across public and private payer plans, the total savings estimated under the combination scenario would be $360 billion vs $95 billion, respectively, the Milliman report said.
“Policymakers should be asking if biosimilars are challenging every biologic drug that has reached its end of exclusivity (or nearly so), and whether that competitive pressure is meaningfully driving down net prices for both the innovator and its competing biosimilars. Today’s biosimilar market evinces neither of these features,” Bach, Mark R. Trusheim, MSc, and Nancy Yu, MBA, argue in their report titled “Biosimilars: Market Changes Do Not Equal Policy Success.”
The originator products facing biosimilar competition currently in the US market are a small minority compared with the number of biologics that still do not face such competition, the investigators argue. “That amounts to only 15% of all biologic drugs that were past exclusivity facing any competition.” Further, there’s little hope for dramatic improvement, they contend. “The market will not stay like this over the next decade, but it isn’t likely to improve that much either.”
According to the Milliman report, the P-quad proposal for a 10% cap on profits would apply to biosimilars as well, and this has the potential to discourage originator manufacturers and biosimilar developers from entering the market because they would not be allowed to include in their pricing the cost of original product investment or extra padding for future drug development.
Milliman also notes that, historically, in the 24-month window after launch, biosimilars have been much less successful than generics at achieving market share over more costly originator products. “Biosimilar market share varies considerably by product and time from launch, with 30% on average expected after 24 months,” the report said. By contrast, generic products have captured 70% to 90% market share within 2 years of launch.
Further, biosimilars can’t be grabbed off a stock room or pharmacy shelf like generic products. Availability is often limited by geographic areas, health care institutions may have different usage policies, and manufacturer rebates are a significant factor determining which biosimilars are accepted and whether originators are preferred by payers.
Milliman considered 3 scenarios to obtain a comparison of projected savings from the P-quad system: no biosimilar competition, the current environment in which biosimilars and originator products compete, and the P-quad system where allowed profits are capped after 12 years of exclusivity.
The following were the estimated savings (approximate) for the P-quad system vs the current system, according to the Milliman analysis:
The P-quad concept assumed a net price decrease of 65% on average for originator products and biosimilars combined; and for a scenario that doesn’t include biosimilars for 41 biologic products, P-quad would increase federal savings by $40 billion over the 2021 to 2025 period, the Milliman report estimated.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.